Europe Prostate Cancer Nuclear Medicine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)
The Europe prostate cancer nuclear medicine market is expected to grow from US$ 141.43 million in 2022 to US$ 262.34 million by 2028; it is estimated to grow at a CAGR of 10.8% from 2022 to 2028.
Cancer greatly impacts the health of patients and survivors and their financial conditions. After diagnosis, a person with prostate cancer is expected to pay around US$ 2,800 per month for treatment. However, depending on the insurance type and government help, these prices can be high or cheap. Costs also depend on the country and the facilities being used. Healthcare systems are increasingly embracing risk-based payment techniques in which they are responsible for their patient's healthcare costs. Healthcare systems are under pressure to provide evidence-based and efficient care in this environment. Cancer screening is an area where health systems are required to align practice with evidence-based guidelines. According to research, many individuals, notably the elderly and those with short life expectancies, are routinely screened for cancer when they are unlikely to benefit. Screening and subsequent treatment have significant downstream expenses. Hence, the high cost related to prostate cancer indirectly restrains the growth of the prostate cancer nuclear medicine diagnostics markets.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe prostate cancer nuclear medicine market. The Europe prostate cancer nuclear medicine market is expected to grow at a good CAGR during the forecast period.
Europe Prostate cancer nuclear medicine Market Revenue and Forecast to 2028 (US$ Million)
Europe Prostate cancer nuclear medicine Market Segmentation
The Europe prostate cancer nuclear medicine market is segmented into type, PET product, end user, and country. Based on type, the Europe prostate cancer nuclear medicine market is divided into PET and SPECT. The PET dominated the Europe prostate cancer nuclear medicine market in 2022. Based on PET product, the Europe prostate cancer nuclear medicine market is categorized into F-18, C-11, and Ga68-PSMA. The F-18 segment dominated the Europe prostate cancer nuclear medicine market in 2022. Based on end user, the Europe prostate cancer nuclear medicine market is categorized into hospitals, clinics, and others. The hospitals segment dominated the Europe prostate cancer nuclear medicine market in 2022. Based on country, the Europe prostate cancer nuclear medicine market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The Germany segment dominated the Europe prostate cancer nuclear medicine market in 2022.
Blue Earth Diagnostics Limited; ImaginAb; Curium; Jubilant Radiopharma; ABX advanced biochemical compounds GmbH; Telix Pharmaceuticals Ltd; Novartis AG; Theragnostics; and Lantheus Medical Imaging, Inc. by Altair are among the leading companies in the Europe prostate cancer nuclear medicine market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By Type
1.3.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product
1.3.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
1.3.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Prostate Cancer
5.1.2 Increasing Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 Rising Cost Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Expanding Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Rising Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
6. Prostate Cancer Nuclear Medicine Diagnostics Market– Europe Analysis
6.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis
7. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type
7.1 Overview
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)
7.3 SPECT
7.3.1 Overview
7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
7.4 PET
7.4.1 Overview
7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
8. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product
8.1 Overview
8.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)
8.3 F-18
8.3.1 Overview
8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.4 C-11
8.4.1 Overview
8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
8.5 GA 68 PSMA
8.5.1 Overview
8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By End User
9.1 Overview
9.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Prostate Cancer Nuclear Medicine Diagnostics Market – By Country Analysis
10.1 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market
10.1.1 Overview
10.1.2 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
10.1.2.1 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.4 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.5 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.4 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.5 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 UK: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.4 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.5 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.1 Overview
10.1.2.4.2 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.3 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.5 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.1 Overview
10.1.2.5.2 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.3 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.4 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.1 Overview
10.1.2.6.2 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.3 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.4 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.5 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
11. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Blue Earth Diagnostics Limited
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 ImaginAb
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Curium
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Jubilant Radiopharma
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 ABX advanced biochemical compounds GmbH
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Telix Pharmaceuticals Ltd.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Novartis AG
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Theragnostics
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Lantheus Medical Imaging, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 5. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 6. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 9. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 11. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 12. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 15. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 19. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 20. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market
Table 21. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market
LIST OF FIGURES
Figure 1. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
Figure 2. Europe Prostate Cancer Nuclear Medicine Diagnostics Market, By Country
Figure 3. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
Figure 4. PET Segment Held Largest Share of Type Segment in Prostate Cancer Nuclear Medicine Diagnostics Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Europe Experts Opinion
Figure 8. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Impact Analysis of Drivers and Restraints
Figure 9. Europe Prostate Cancer Nuclear Medicine Diagnostics Market– Revenue Forecast and Analysis – 2020 - 2028
Figure 10. Europe Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2022 & 2028 (%)
Figure 11. Europe SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Europe PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Europe Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2022 & 2028 (%)
Figure 14. Europe F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. Europe C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. Europe GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Europe Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User - 2022 & 2028 (%)
Figure 18. Europe Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. Europe Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 20. Europe Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 22. Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)
Figure 23. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. France: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. UK: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028
- Blue Earth Diagnostics Limited
- ImaginAb
- Curium
- Jubilant Radiopharma
- ABX advanced biochemical compounds GmbH
- Telix Pharmaceuticals Ltd
- Novartis AG
- Theragnostics
- Lantheus Medical Imaging, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe prostate cancer nuclear medicine market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe prostate cancer nuclear medicine market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe prostate cancer nuclear medicine market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution